ChurchillD.N., ThorpeK.E., NolphK.D., KeshaviahP.R., OreopoulosD.G., PageD.Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients. The Canada-USA (CANUSA) Peritoneal Dialysis Study Group.J Am Soc Nephrol1998; 9: 1285–92.
DaviesS.J.Longitudinal relationship between solute transport and ultrafiltration capacity in peritoneal dialysis patients.Kidney Int2004; 66: 2437–45.
4.
GillerotG., GoffinE., MichelC., EvenepoelP., Van BiesenW., TintillerM.Genetic and clinical factors influence the baseline permeability of the peritoneal membrane.Kidney Int2005; 67: 2477–87.
5.
MargettsP., ChurchillD.N.Acquired ultrafiltration dysfunction in peritoneal dialysis patients.J Am Soc Nephrol2002; 13: 2787–94.
6.
NiJ., MoulinP., GianelloP., FeronO., BalligandJ.L., DevuystO.Mice that lack endothelial nitric oxide synthase are protected against functional and structural modifications induced by acute peritonitis.J Am Soc Nephrol2003; 14: 3205–16.
7.
GillerotG., DevuystO.Changes in the peritoneal membrane with peritoneal dialysis: molecular mechanisms.Clin Nephrol2003; 60: 1–6.
8.
MiyataT., DevuystO., KurokawaK., van Ypersele de StrihouC.Toward better dialysis compatibility: advances in the biochemistry and pathophysiology of the peritoneal membranes.Kidney Int2002; 61: 375–86.
9.
TopleyN.Membrane longevity in peritoneal dialysis: impact of infection and bio-incompatible solutions.Adv Ren Replace Ther1998; 5: 179–84.
10.
NakaT., NishimotoN., KishimotoT.The paradigm of IL-6: from basic science to medicine.Arthritis Res2002; 4(Suppl 3): S233–42.
11.
JonesS.A., HoriuchiS., TopleyN., YamamotoN., FullerG.M.The soluble interleukin 6 receptor: mechanisms of production and implications in disease.FASEB J2001; 15: 43–58.
12.
HurstS.M., WilkinsonT.S., McLoughlinR.M., JonesS., HoriuchiS., YamamotoN.IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation.Immunity2001; 14: 705–14.
13.
McLoughlinR.M., WitowskiJ., RobsonR.L., WilkinsonT.S., HurstS.M., WilliamsA.S.Interplay between IFN-gamma and IL-6 signaling governs neutrophil trafficking and apoptosis during acute inflammation.J Clin Invest2003; 112: 598–607.
McLoughlinR.M., JenkinsB.J., GrailD., WilliamsA.S., FieldingC.A., ParkerC.R.IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation.Proc Natl Acad Sci U S A2005; 102: 9589–94.
16.
JorresA., LudatK., LangJ., SanderK., GahlG.M., FreiU.Establishment and functional characterization of human peritoneal fibroblasts in culture: regulation of interleukin-6 production by proinflammatory cytokines.J Am Soc Nephrol1996; 7: 2192–201.
17.
PanichiV., MaggioreU., TaccolaD., MiglioriM., RizzaG.M., ConsaniC.Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients.Nephrol Dial Transplant2004; 19: 1154–60.
18.
Pecoits-FilhoR., AraujoM.R., LindholmB., StenvinkelP., AbensurH., RomaoJ.E.Plasma and dialysate IL-6 and VEGF concentrations are associated with high peritoneal solute transport rate.Nephrol Dial Transplant2002; 17: 1480–6.
19.
Pecoits-FilhoR., CarvalhoM.J., StenvinkelP., LindholmB., HeimbürgerO.Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis.Perit Dial Int2006; 26: 53–63.
20.
Pecoits-FilhoR., StenvinkelP., WangA.Y., HeimburgerO., LindholmB.Chronic inflammation in peritoneal dialysis: the search for the holy grail?Perit Dial Int2004; 24: 327–39.
21.
ParikovaA., ZweersM.M., StruijkD.G., KredietR.T.Peritoneal effluent markers of inflammation in patients treated with icodextrin-based and glucose-based dialysis solutions.Adv Perit Dial2003; 19: 186–90.
